ReviewCurrent neuropharmacology2020
An Overview of the Heterogeneity of Major Depressive Disorder: Current Knowledge and Future Prospective.
Review in Current neuropharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 3 syntheses or guidelines pooled it, 93 citations in OpenAlex.
- Neurometabolics of the anterior cingulate cortex (ACC) in major depressive disorder (MDD): A systematic review and meta-analysis.NeuroImage. Clinical · 2026Pooled it
- Pooled it
- Association of peripheral manifestation of brain-derived neurotrophic factor with depression: A meta-analysis.Brain and behavior · 2022Pooled it
- Effect of probiotic supplement on improvement of depressive symptoms in patients with substance-induced depressive disorder: a randomized, double-blind, placebo-controlled clinical trial.BMC psychiatry · 2026Trial
- Using machine learning to forecast symptom changes among subclinical depression patients receiving stepped care or usual care.Journal of affective disorders · 2023Trial
- Investigating functional connectivity differences during food vs. monetary reward processing across appetitive phenotypes of major depressive disorder.Journal of affective disorders · 2026Article
- Distinct depressive-like behavioural phenotypes in mice exhibit unique patterns of transcriptional perturbations across habenular cell subtypes.Molecular psychiatry · 2026Article
- Exosomes in depression: mechanistic insights, diagnostic potential, and therapeutic opportunities.Molecular psychiatry · 2026Review
- Low Dose Ketamine Preconditions Astrocyte Mitochondria to Achieve Antidepressant Efficacy via Adenosine, Humanin, and Melatonin Upregulation and Efflux.Alpha psychiatry · 2026Article
- EEG Signatures of Melancholia: An Update.NeuroSci · 2026Review
- The Impact of Pre-Existing Psychiatric Disorders on Gastric Cancer Stage and Mortality in Older Adults.Cancer medicine · 2026Article
- Transcutaneous auricular vagus nerve stimulation for major depressive disorder: current evidence and future research directions.Frontiers in psychiatry · 2026Review
- New Antidepressant Development in the Treatment of Depression.Advances in experimental medicine and biology · 2026Review
- Harnessing Dietary Tryptophan: Bridging the Gap Between Neurobiology and Psychiatry in Depression Management.International journal of molecular sciences · 2026Review
- Maintenance pharmacotherapy after electroconvulsive therapy in inpatients with major depressive disorder: 198 prescriptions in a real-world clinical setting.BMC psychiatry · 2025Article
- Neural Activity Disparities in Deficiency and Excess Patterns of Depression: Protocol for a Systematic Review and Meta-Analysis.JMIR research protocols · 2025Article
- Neuroimmune, metabolic and oxidative stress pathways in major depressive disorder.Nature reviews. Neurology · 2025Review
- Observational
- An Overview of the Systematic Reviews About the Efficacy of Fluvoxamine on Depression.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Human Umbilical Cord Mesenchymal Stem Cells Ameliorated Chronic Unpredictable Mild Stress-Induced Depression and Anxiety by Alleviating Neuroinflammation.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Major depressive disorder (MDD) is estimated to impose maximum debilitating effects on the society by 2030, with its critical effects on health, functioning, quality of life and concomitant high levels of morbidity and mortality. Yet, the disease is inadequately understood, diagnosed and treated. Moreover, with the recent drastic rise in the pace of life, stress has materialized as one of the most potent environmental factors for depression. In this scenario, it is important to understand the modern pathogenetic hypotheses and mechanisms, and possibly try to shift from the traditional approaches in depression therapy. These include the elaboration of pathophysiological changes in heterogeneous systems such as genetic, epigenetic, serotonergic, noradrenergic, gammaaminobutyric acid, glutamatergic and endocannabinoid systems, neurotrophic factors, HPA axis, immune system as well as cellular stress mechanisms. These components interact with each other in a complex matrix and further elucidation of their mechanism and cascade pathways are needed. This might aid in the identification of MDD subtypes as well as the development of sophisticated biomarkers. Further, characterization might also aid in developing multitargeted therapies that hold much promise as compared to the conventional monoamine based treatment. New candidate pharmacons, refined psychotherapeutic modalities, advanced neuro-surgical and imaging techniques as well as the implementation of pharmacokinetic, pharmacogenetic prescribing guidelines constitute the emerging expanses of MDD treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.